ArticleCancer management and research2020
Prognosis of Intravascular Large B Cell Lymphoma (IVLBCL): Analysis of 182 Patients from Global Case Series.
Article in Cancer management and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 45 citations in OpenAlex.
- CD19-directed CAR T therapy for intravascular large B-cell lymphoma.Haematologica · 2026Article
- Atypical Presentation of Intravascular Large B-cell Lymphoma After Treatment for Antineutrophil Cytoplasmic Antibody-associated Vasculitis.Internal medicine (Tokyo, Japan) · 2026Article
- Article
- [Intravascular large B-cell lymphoma of the nasal turbinate presenting with hemophagocytic lymphohistiocytosis: a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- Long-term Survivor of Intravascular Central Nervous System (CNS) Lymphoma: An Unusual Phenomenon.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
- Intravascular large B-cell lymphoma presenting as encephalomyelitis diagnosed by renal biopsy: a case report.BMC neurology · 2025Article
- Review
- Clinical features and prognostic factors of intravascular large B-cell lymphoma: a cohort study of 20 patients from 2018 to 2024.The oncologist · 2025Article
- Unmet needs of patients with intravascular large B-cell lymphoma: three case reports and a literature review.Journal of Zhejiang University. Science. B · 2025Review
- CT-Imaging Manifestations and Diagnostic Insights in Pulmonary Intravascular Large B-Cell Lymphoma: A Case Series and Literature Review.Cancer reports (Hoboken, N.J.) · 2025Review
- Prognostic factors of patients with intravascular large B cell lymphoma: a multicenter study in China.Frontiers in oncology · 2025Article
- Article
- In the era of targeted therapy and immunotherapy: advances in the treatment of large B-cell lymphoma of immune-privileged sites.Frontiers in immunology · 2025Review
- Primary pulmonary intravascular large B‑cell lymphoma: Indications from cytomorphology findings through CT‑guided puncture: A case report.Oncology letters · 2025Article
- Clinical manifestations and outcomes of patients with intravascular large B-cell lymphoma with neurological involvement: highlighting longitudinally extensive myelopathy as a distinct feature.BMJ neurology open · 2025Article
- A case report and literature review of a rare lymphoma with repeated fever by pain and numbness in both lower limbs.Frontiers in medicine · 2025Article
- Intraocular Lymphoma: A Review.Journal of ophthalmic & vision research · 2025Review
- Rare intravascular large B-cell lymphoma (IVLBCL) can cause atypical intracerebral haemorrhage and mislead diagnostics.BMJ case reports · 2024Article
- Prognostic Impacts of Age, Diagnosis Time, and Relapses in Primary CNS Lymphoma.Journal of clinical medicine · 2024Article
- Cutaneous Intravascular Hematolymphoid Entities: A Review.Diagnostics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study provides an overview of the prognosis of intravascular large B cell lymphoma (IVLBCL) over the past 10 years and analyzes the possible relevant factors. PATIENTS AND
methodsWe conducted a literature search of case reports, case series, and retrospective studies of IVLBCL published from January 2008 to July 2018. After excluding inappropriate data, 103 publications were selected for the analysis. Statistical analyses of different treatment modalities, the effect of blood-brain barrier (BBB)-penetrating drugs, and prognostic factors for outcomes were performed.
resultsIn total, 182 pathologically confirmed cases of IVLBCL were included in our study. The results revealed that the 1- and 3-year overall survival rates were 42.3 and 11.5%, respectively, whereas the median overall survival was 340 days. Overall survival (450 days vs 180 days) and progression-free survival (420 days vs 150 days) were significantly longer in patients who received rituximab-containing regimens than in those treated with other regimens. For IVLBCL involving the CNS, regimens containing BBB-penetrating drugs failed to provide an additional survival benefit. In addition, lactic dehydrogenase levels ≥700 U/L, CNS involvement, and hemophagocytic syndrome were identified as unfavorable risk factors in patients with IVLBCL, whereas skin involvement appeared to be a protective factor.
conclusionRituximab-containing chemotherapy can improve the outcomes of patients with IVLBCL, but the prognosis remains unsatisfactory. Treatment regimens containing BBB-penetrating drugs failed to improve outcomes in patients with CNS-involved IVLBCL. Several factors affect the prognosis of patients with IVLBCL, and further research on the underlying mechanisms is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.